Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Radiotherapy for Safe Hypofractionation (ART-Hypo): A Bayesian Registry-Based Randomized Controlled Trial

NCT07516210 is registered in ClinicalTrials.gov with Centre hospitalier de l'Université de Montréal (CHUM) as lead sponsor.

NCT NCT07516210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07516210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Radiotherapy for Safe Hypofractionation (ART-Hypo): A Bayesian Registry-Based Randomized Controlled Trial
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
May 31, 2030
Enrollment
264 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cervical cancer, endometrial cancer, prostate cancer, rectal cancers